These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. C644-0303, a small-molecule inhibitor of the Wnt/β-catenin pathway, suppresses colorectal cancer growth. Yan Y; Zhang Y; Li M; Zhang Y; Zhang X; Zhang X; Xu Y; Wei W; Wang J; Xu X; Song Q; Zhao C Cancer Sci; 2021 Nov; 112(11):4722-4735. PubMed ID: 34431598 [TBL] [Abstract][Full Text] [Related]
25. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes. Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443 [TBL] [Abstract][Full Text] [Related]
26. miR-155 Is Downregulated in Familial Adenomatous Polyposis and Modulates WNT Signaling by Targeting AXIN1 and TCF4. Prossomariti A; Piazzi G; D'Angelo L; Miccoli S; Turchetti D; Alquati C; Montagna C; Bazzoli F; Ricciardiello L Mol Cancer Res; 2018 Dec; 16(12):1965-1976. PubMed ID: 30072583 [TBL] [Abstract][Full Text] [Related]
27. Scutellaria barbata D. Don inhibits colorectal cancer growth via suppression of Wnt/β-catenin signaling pathway. Wei LH; Lin JM; Chu JF; Chen HW; Li QY; Peng J Chin J Integr Med; 2017 Nov; 23(11):858-863. PubMed ID: 29080197 [TBL] [Abstract][Full Text] [Related]
28. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta. Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278 [TBL] [Abstract][Full Text] [Related]
29. USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination. Novellasdemunt L; Foglizzo V; Cuadrado L; Antas P; Kucharska A; Encheva V; Snijders AP; Li VSW Cell Rep; 2017 Oct; 21(3):612-627. PubMed ID: 29045831 [TBL] [Abstract][Full Text] [Related]
30. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969 [TBL] [Abstract][Full Text] [Related]
32. Evidence for tankyrases as antineoplastic targets in lung cancer. Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985 [TBL] [Abstract][Full Text] [Related]
33. LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors. de la Roche M; Ibrahim AE; Mieszczanek J; Bienz M Cancer Res; 2014 Mar; 74(5):1495-505. PubMed ID: 24419084 [TBL] [Abstract][Full Text] [Related]
34. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models. Buchstaller HP; Anlauf U; Dorsch D; Kögler S; Kuhn D; Lehmann M; Leuthner B; Lodholz S; Musil D; Radtki D; Rettig C; Ritzert C; Rohdich F; Schneider R; Wegener A; Weigt S; Wilkinson K; Esdar C J Med Chem; 2021 Jul; 64(14):10371-10392. PubMed ID: 34255518 [TBL] [Abstract][Full Text] [Related]
35. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling. McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298 [TBL] [Abstract][Full Text] [Related]